DE69830185D1 - Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen - Google Patents

Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen

Info

Publication number
DE69830185D1
DE69830185D1 DE69830185T DE69830185T DE69830185D1 DE 69830185 D1 DE69830185 D1 DE 69830185D1 DE 69830185 T DE69830185 T DE 69830185T DE 69830185 T DE69830185 T DE 69830185T DE 69830185 D1 DE69830185 D1 DE 69830185D1
Authority
DE
Germany
Prior art keywords
secretin
autistic
relationship
syndromes
differential diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69830185T
Other languages
English (en)
Inventor
Karoly Horvath
Victoria Beck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repligen Corp
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Application granted granted Critical
Publication of DE69830185D1 publication Critical patent/DE69830185D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/645—Secretins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
DE69830185T 1997-05-19 1998-05-19 Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen Expired - Fee Related DE69830185D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4704997P 1997-05-19 1997-05-19
PCT/US1998/010224 WO1998052593A1 (en) 1997-05-19 1998-05-19 Method for assisting in differential diagnosis and treatment of autistic syndromes

Publications (1)

Publication Number Publication Date
DE69830185D1 true DE69830185D1 (de) 2005-06-16

Family

ID=21946797

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830185T Expired - Fee Related DE69830185D1 (de) 1997-05-19 1998-05-19 Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen

Country Status (8)

Country Link
US (3) US6020310A (de)
EP (1) EP1019072B1 (de)
JP (1) JP2002501616A (de)
AT (1) ATE295176T1 (de)
AU (1) AU748147B2 (de)
CA (1) CA2290556A1 (de)
DE (1) DE69830185D1 (de)
WO (1) WO1998052593A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150321A (en) * 1996-12-12 2000-11-21 Colgate-Palmolive Co. Chemical linker compositions
DE69830185D1 (de) * 1997-05-19 2005-06-16 Repligen Corp Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
US6020314A (en) * 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders
DE19902773A1 (de) * 1999-01-25 2000-07-27 Sertuerner Arzneimittel Gmbh Anticholestatische Wirksamkeit von Luteolin
MXPA01008038A (es) * 1999-02-08 2002-04-24 Johnson 6 Johnson Derivados anticonvulsionantes utiles en el tratamiento de autismo.
WO2000068433A2 (en) * 1999-05-06 2000-11-16 Children's Hospital Of Los Angeles Autism gene
AU3641401A (en) 1999-11-05 2001-05-14 Joseph A. Rogoff Secretin and secretin pharmaceuticals for treating lactose intolerance
DE19953339A1 (de) * 1999-11-05 2001-05-17 Goldham Pharma Gmbh Secretinfragmente
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
WO2001079837A1 (en) * 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
GB0016441D0 (en) * 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US6660831B2 (en) * 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
JP2005508338A (ja) * 2001-10-04 2005-03-31 プロテイン セラピューティクス、インク． 免疫性疾患を処置するためのガンマグロブリンの使用
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
WO2004100899A2 (en) * 2003-05-13 2004-11-25 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
JP2005082490A (ja) * 2003-09-04 2005-03-31 Kirin Brewery Co Ltd 脳機能改善剤
US7947285B2 (en) * 2003-12-12 2011-05-24 Fein Seymour H Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
US7381698B2 (en) * 2003-12-12 2008-06-03 Chirhoclin, Inc. Methods for treatment of acute pancreatitis
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (de) 2008-07-01 2019-06-12 Curemark, Llc Verfahren und zusammensetzungen zur behandlung von symptomen von neurologischen und geistesstörungen
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
NZ593823A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or the prevention of infections by e. coli
AU2010203709B2 (en) 2009-01-06 2014-05-22 Galenagen, Llc Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2443259A4 (de) * 2009-06-16 2012-10-10 Univ Columbia Biomarker für autismus und verwendungen davon
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
CA2778181A1 (en) 2009-10-26 2011-05-05 Thomas Julius Borody Therapy for enteric infections
RU2460466C2 (ru) * 2010-10-28 2012-09-10 Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава") Способ определения уровня нервно-психического развития ребенка первого года жизни
US8586384B2 (en) * 2011-04-05 2013-11-19 Olympus Corporation Method of collecting duodenal specimen to detect upper digestive system disease without using pancreatic or bile stimulant
US8529547B2 (en) * 2011-04-05 2013-09-10 Olympus Corporation Method of collecting specimen and method of diagnosing subject to detect upper digestive system disease
CN103460045B (zh) 2011-04-05 2016-01-20 奥林巴斯株式会社 胰脏检查方法及胰脏检查试剂盒
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
CN105358987A (zh) * 2013-07-02 2016-02-24 奥林巴斯株式会社 胰腺病标记物检测用十二指肠液试样的确定方法、以及胰腺病标记物的检测方法
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
CN109182577B (zh) * 2018-09-25 2022-03-15 深圳市英马诺生物科技有限公司 自闭症生物标志物及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
JPS5029005B2 (de) * 1972-05-08 1975-09-19
US3987014A (en) * 1974-01-10 1976-10-19 Becton, Dickinson And Company Secretin intermediates and derivatives
DE2615229C2 (de) * 1976-04-08 1984-05-24 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung und Reinigung von Sekretin
US4086220A (en) * 1976-08-09 1978-04-25 G. D. Searle & Co. Fragments of secretin
EP0021184B1 (de) * 1979-06-13 1984-02-08 Hoechst Aktiengesellschaft Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
JPS58140024A (ja) * 1982-02-15 1983-08-19 Eisai Co Ltd セクレチンの精製方法
DE3328793A1 (de) * 1983-08-10 1985-02-28 Hoechst Ag, 6230 Frankfurt Herstellung von sekretin
SE454513B (sv) * 1985-03-11 1988-05-09 Kabigen Ab Humant sekretin samt kompositioner innehallande detta
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5094837A (en) * 1990-01-22 1992-03-10 Wayne State University Method for use of magnetic resonance imaging to image pancreas using secretin
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5380872A (en) 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
DE69426415T2 (de) 1993-01-29 2001-07-26 Aradigm Corp Intrapulmonares hormonabgabesystem
US5527825A (en) * 1994-04-06 1996-06-18 University Of Arkansas Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
DE69830185D1 (de) * 1997-05-19 2005-06-16 Repligen Corp Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
FR2767830B1 (fr) 1997-08-26 2000-02-04 Sod Conseils Rech Applic Oligonucleotides permettant l'identification de precurseurs d'hormones polypeptidiques amidees

Also Published As

Publication number Publication date
US6498143B1 (en) 2002-12-24
AU748147B2 (en) 2002-05-30
AU7688598A (en) 1998-12-11
EP1019072B1 (de) 2005-05-11
JP2002501616A (ja) 2002-01-15
ATE295176T1 (de) 2005-05-15
US6020310A (en) 2000-02-01
EP1019072A1 (de) 2000-07-19
US20040146495A1 (en) 2004-07-29
CA2290556A1 (en) 1998-11-26
EP1019072A4 (de) 2002-06-19
US7091182B2 (en) 2006-08-15
WO1998052593A1 (en) 1998-11-26

Similar Documents

Publication Publication Date Title
DE69830185D1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
NO20002005L (no) FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel
ATE322283T1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
ATE66374T1 (de) Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE44156T1 (de) Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie.
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
SU1169655A1 (ru) Способ лечени тромбооблитерирующих заболеваний артерий конечностей
SU1222274A1 (ru) Способ лечени больных хроническим сальпингоофоритом
RU2043103C1 (ru) Средство, уменьшающее внешнесекреторную недостаточность поджелудочной железы при хроническом панкреатите
SU628926A1 (ru) Способ лечени пародонтоза
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
DK563886A (da) Terapeutisk komposition
RU93018663A (ru) Способ хирургического лечения цирроза печени (его варианты)

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee